ROCKVILLE, Md., Nov. 23, 2020 /PRNewswire/ -- REGENXBIO Inc.
(Nasdaq: RGNX), a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy based on its proprietary NAV® Technology
Platform, today announced it will present at the following December
investor conferences, which will each be held in a virtual meeting
format:
Piper Sandler 32nd
Annual Virtual Healthcare Conference
Fireside Chat:
Pre-recorded
Evercore ISI 3rd Annual HealthCONx
Conference
Fireside Chat: Thursday, December 3, 2020 at 11:45 a.m. ET
The pre-recorded Piper Sandler
fireside chat is currently available in the Investors section of
REGENXBIO's website at www.regenxbio.com and will be available
for approximately 30 days. A live webcast of the Evercore fireside
chat can be accessed in the same section of REGENXBIO's website,
and an archived replay will be available for approximately 30
days following the presentation.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV
Technology Platform Licensees are applying the NAV Technology
Platform in the development of a broad pipeline of candidates in
multiple therapeutic areas.
Contacts:
Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com
Investors:
Eleanor Barisser, 212-600-1902
eleanor@argotpartners.com
Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/regenxbio-to-present-at-upcoming-investor-conferences-301178926.html
SOURCE REGENXBIO Inc.